Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial.

ABSTRACT:

Background/aims

Birdshot uveitis (BU) is a chronic autoimmune posterior uveitis, mostly affecting middle-aged Caucasians. There is a strong association with HLA-A29 and T-cell activation. Safety and efficacy of abatacept, an inhibitor of T-cell costimulation, is tested in active BU.

Methods

Fifteen patients with active BU were treated with monotherapy of weekly subcutaneous injections of abatacept 125 mg/mL. Time-to-treatment failure was evaluated as a primary outcome. The secondary objective was to evaluate the utility of different outcome measures to monitor disease activity. Safety was evaluated by adverse event reporting and serial blood analyses.

Results

At the year-1 endpoint, there was significant improvement in vitreous haze grade (p=0.0014), central choroidal

SUBMITTER: Schauwvlieghe PP 

PROVIDER: S-EPMC10850705 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature